24 completed, 5 recruiting, 4 unknown, 1 active not recruiting. 10 Phase 3, 6 Phase 2, 4 Phase 1, 4 Phase 4, 2 Not applicable.
Follow recombinant FVIIa: new trials by email Literature Review of recombinant FVIIa trials Research Report on recombinant FVIIa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis Emicizumab, FEIBA, rFVIIa - Hemophilia A | Phase 3 | Recruiting | Emory University | 5 | 2026-09-01 | 2026-08-21 |
| Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531) EPTACOG BETA - Glanzmann Thrombasthenia | Phase 2 | Recruiting | Emory University | 6 | 2025-10-02 | 2025-12-01 |
| A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India Eptacog alfa (NovoSeven) - Severe Postpartum Haemorrhage | Phase 4 | Recruiting | Novo Nordisk A/S | 64 | 2025-08-26 | 2026-09-25 |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 Recombinant Factor VIIa, Biological/Vaccine: Placebo - Intracerebral Hemorrhage | Phase 3 | Recruiting | Joseph Broderick, MD | 350 | 2025-05-06 | 2026-08-20 |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial Recombinant Activated Factor VII (rFVIIa), Placebo - Intracerebral Hemorrhage | Phase 3 | Active not recruiting | Joseph Broderick, MD | 860 | 2021-12-03 | 2026-01-21 |
| Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. TQG203, TQG203/NovoSeven® - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2020-12-01 | 2021-02-24 |
| A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants Milvexian, 4-Factor Prothrombin Complex Concentrate (4F-PCC), Recombinant Human Factor VIIa (rFVIIa) - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 52 | 2020-07-27 | 2025-08-15 |
| NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL Eptacog alfa, Standard of care - Post Partum Hemorrhage | Completed | Leiden University Medical Center | 3322 | 2020-05-01 | 2022-05-11 | |
| Treatment of Hemophilia A Patients With FVIII Inhibitors Nuwiq, Octanate, Wilate - Hemophilia A | Recruiting | Emory University | 120 | 2020-03-17 | 2026-09-23 | |
| Recombinant Factor VII for Intractable Postpartum Haemorrhage recombinant factor VIIa - Post Partum Hemorrhage | Completed | Aljazeera Hospital | 41 | 2019-06-01 | 2022-03-28 | |
| Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors Biosimilar eptacog alfa, activated (AryoSeven), Eptacog alfa, activated (Novoseven) - Hemophilia A or B With Inhibitor | Phase 3 | Completed | AryoGen Pharmed Co. | 48 | 2018-07-23 | 2021-02-04 |
| Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia NovoSeven - Massive Hemorrhage, Massive Blood Loss | Completed | Universiti Sains Malaysia | 76 | 2017-08-21 | 2018-10-10 | |
| A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors Concizumab, Eptacog alfa - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Completed | Novo Nordisk A/S | 26 | 2017-08-10 | 2021-10-22 |
| Activated Factor Seven in Traumatic Retro Peritoneal Hematoma ventilators, aminocaproic acid, Novo Seven - Traumatic Bleeding | Completed | King Abdul Aziz Specialist Hospital | 80 | 2017-05-05 | 2020-06-11 | |
| Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Eptacog alfa, biosimilar, Novoseven - Factor VII Deficiency | Phase 3 | Completed | AryoGen Pharmed Co. | 24 | 2017-03-01 | 2021-02-04 |
| A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa Coagulation FVIIa (Recombinant) - Hemophilia A With Inhibitors, Hemophilia B With Inhibitors | Phase 3 | Completed | Laboratoire français de Fractionnement et de Biotechnologies | 25 | 2015-12-07 | 2022-02-25 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors Emicizumab, rFVIIa, aPCC - Hemophilia A | Phase 3 | Completed | Hoffmann-La Roche | 113 | 2015-11-18 | 2021-06-24 |
| Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency Eptacog alfa (activated) or pdFVII, CSL689 - Congenital Coagulation Factor VII Deficiency | Phase 1 | Completed | CSL Behring | 9 | 2015-07-01 | 2017-04-26 |
| A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan eptacog alfa (activated) - Congenital Bleeding Disorder, Glanzmann's Disease | Completed | Novo Nordisk A/S | 4 | 2014-10-07 | 2017-07-11 | |
| Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen Recombinant Factor VIIa BI (rFVIIa BI) - Hemophilia A, Hemophilia B | Phase 3 | Completed | Baxalta now part of Shire | 40 | 2013-02-20 | 2021-05-11 |
Showing 20 of 35. Sign in to see all of them.
Hemophilia A (10) · Cerebral Hemorrhage (5) · Postpartum Hemorrhage (4) · Hemophilia B (3) · Thrombasthenia (3) · Factor VII Deficiency (2) · Burns (1) · Factor XI Deficiency (1) · Hematologic Diseases (1) · Hemorrhage (1) · Intracranial Hemorrhages (1) · Stroke (1) · Thrombocytopenia (1)
Novo Nordisk A/S (5) · Emory University (3) · AryoGen Pharmed Co. (2) · Joseph Broderick, MD (2) · Sheba Medical Center (2) · Aljazeera Hospital (1) · Baxalta now part of Shire (1) · CSL Behring (1) · Centre Hospitalier Universitaire de Nīmes (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dr. David Gladstone (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Hoffmann-La Roche (1) · Janssen Research & Development, LLC (1)
United States (11) · Germany (6) · Italy (6) · Japan (6) · Spain (6) · United Kingdom (5) · Canada (4) · France (3) · Netherlands (3) · Ukraine (3) · Austria (2) · Iran (2) · Israel (2) · Malaysia (2) · Norway (2)
Massimo Iacobelli, MD (2) · Alex Veldman (1) · Alfonso Iorio (1) · Andrew Demchuk, MD (1) · Catherine Deneux-Tharaux, MD, PhD (1) · Chong Soon Eu, MD, MMed (1) · Dacia Henriquez, MD, PhD (1) · David J Gladstone, MD (1) · Elena Santagostino, MD, PhD (1) · Erik Berntorp, MD, PhD (1) · Hellen Edwards, MD, PhD (1)
PMID 37870112, PMID 16990605, PMID 18289410, PMID 23403322, PMID 24763923, PMID 25594352, PMID 28691557, PMID 31424491, PMID 31444162, PMID 34427473, PMID 34589194, PMID 35290453, PMID 35939785, PMID 36756899, PMID 39654449, PMID 40674256, PMID 40765904, PMID 41653933, PMID 42440100
2005 (2), U01NS110772 (2), 2014 (1), 2015 (1), 2016 (1), 2019 (1)